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A B S T R A C T
Purpose
Chemohormonal therapy with docetaxel and androgen deprivation therapy (ADT+D) for metastatic
hormone-sensitive prostate cancer improves overall survival as comparedwith androgen deprivation
therapy (ADT) alone. We compared the quality of life (QOL) between patients with metastatic
hormone-sensitive prostate cancer whowere treated with ADT+D and thosewhowere treated with
ADT alone.
Methods
Menwere randomly assigned to ADT+ D (six cycles) or to ADT alone. QOLwas assessed by Functional
Assessment of Cancer Therapy-Prostate (FACT-P), FACT-Taxane, Functional Assessment of Chronic
Illness Therapy-Fatigue, and the Brief Pain Inventory at baseline and at 3, 6, 9, and 12 months. The
Wilcoxon signed rank test was used to examine changes over time. Mixed-effect models compared the
QOL between arms at each time point.
Results
Seven hundred ninety men were randomly assigned (ADT+D [n = 397] and ADT[ n = 393]) and
completed FACT-P (90% at baseline, 86% at 3 months, 83% at 6 months, 78% at 9 months, and
77% at 12months). ADT+D patients reported a statistically significant decline in FACT-P at 3months
(P, .001) but FACT-P did not differ significantly between baseline and 12 months (P = .38). ADT+D
FACT-P scores were significantly lower at 3 months (P = .02) but significantly higher at 12 months
(P = .04) when comparedwith ADT FACT-P scores. Differences did not exceed theminimal clinically
important difference at any time point. ADT+D patients reported significantly lower Functional
Assessment of Chronic Illness Therapy-Fatigue scores at 3months than did ADT patients (P, .001).
Over time, both arms reported significantly poorer FACT-Taxane scores (P, .001) when compared
with baseline. Brief Pain Inventory scores were similar between arms.
Conclusion
AlthoughADT+Dwasassociatedwith statisticallyworseQOLat 3months,QOLwasbetter at 12months
for ADT+D patients than for ADT patients. Both arms reported a similar minimally changed QOL over
time, suggesting that ADT+D is not associated with a greater long-term negative impact on QOL.
J Clin Oncol 36:1088-1095. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Prostate cancer (PCa) is the second most com-
mon cancer diagnosed in men worldwide, and is
the third leading cause of cancer death among
American men.1,2 Two landmark studies have
demonstrated prolonged survival for men with
metastatic hormone-sensitive prostate cancer
(mHSPC) treated with chemohormonal therapy.3,4
A prospectively defined subgroup analysis in E3805
with long-term follow-up further demonstrated
that the survival benefit associated with treatment
was driven by men with high-volume mHSPC.5
Chemohormonal therapy has since become a stan-
dard option for the treatment of mHSPC with
adequate performance status, particularly among
men with high-volume disease.6
Quality of life (QOL) is of paramount im-
portance for men with metastatic PCa because
the disease is incurable and it commonly afflicts
elderly men with multiple comorbid illnesses or
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a borderline performance status. In the PCa population, docetaxel
has an adverse event profile, with up to a 51% risk of grade 3 to 5
adverse events including neutropenic fever, peripheral neuropathy,
and fluid retention.3,4,7 It has been hypothesized that QOL in this
population is the product of the alleviation of disease-related
symptoms and the introduction of treatment-related symptoms.8
Understanding QOL as it relates to particular therapies is critical to
inform patient-provider treatment decisions.
To more clearly understand the burden of treatment, E3805
evaluated the change in QOL over 12 months to describe QOL
outcomes associated with chemohormonal therapy in men with
mHSPC.
METHODS
Study Oversight
The primary objective of E3805 was to assess whether chemo-
hormonal therapy was associated with prolonged survival as compared
with androgen deprivation therapy (ADT) alone in men with mHSPC.3 A
patient-reported QOL assessment was performed as a secondary outcome
of E3805. As detailed in a previous publication, E3805 was designed and
coordinated by the Eastern Cooperative Oncology Group (ECOG; now
ECOG-ACRIN) and was approved by local institutional review boards at
participating institutions.3 Sanofi provided docetaxel (before progression
when receiving ADT) and a grant to ECOG-ACRIN. The company did
not participate in the design of the study, data collection or analysis, or
manuscript preparation.
Patients
Participants were enrolled by ECOG-ACRIN, Southwest Oncology
Group, Alliance for Clinical Trials in Oncology, and NRG Oncology, and
the study was supported by the Clinical Trials Support Unit.3 Eligible men
had an ECOG performance status of # 2 without significant organ
dysfunction, a pathologic diagnosis of prostate adenocarcinoma, and
radiographic evidence of metastatic disease. Exposure to previous ADT
for # 24 months was permissible if . 12 months had passed since ex-
posure. Men without progression when receiving ADT for mHSPC were
eligible if they had started ADTwithin 120 days. All participants provided
written informed consent.
Treatment Plan, Random Assignment, and Stratification
Men were randomly assigned to receive treatment with chemo-
hormonal therapy (docetaxel 75 mg/m2 once every 3 weeks for six cycles
plus ADT; ADT+D) or with ADT alone.3 Patients were stratified by the
extent of metastatic burden (high volume, defined as the presence of four
or more bone metastases with one or more outside of the vertebral bodies
and pelvis or visceral metastases; and low volume).3 Dose modifications to
ADTwere not allowed, and dose modifications for docetaxel were limited.
Dose modification details are in the Data Supplement.
Data Collection
QOL surveys were administered at baseline and at 3, 6, 9, and 12months.
When necessary, staff provided neutral assistance for survey completion and
prompted patients to complete incomplete items. If the patient refused, it was
indicated on the questionnaire. If a patient missed a scheduled appointment,
the questionnaire was completed by telephone on the appointed date or at the
rescheduled appointment.
Measures
Primary outcome: Overall QOL by Functional Assessment of Cancer
Therapy-Prostate. Functional Assessment of Cancer Therapy-Prostate
(FACT-P; version 4) is a patient-reported measure of QOL that con-
tains 39 items distributed over five subscales: Physical (seven items),
Social or Familial (seven items), Emotional (six items), and Functional
(seven items) well-being, and additional concerns related to the Prostate
Cancer Scale (12 items).9 Higher scores indicate better QOL. Clinically
meaningful change on the FACT-P total score was considered a change of
6 to 10 points.10
Secondary outcomes: Treatment and disease-related QOL. The Trial
Outcome Index (TOI) is a measure of physical and functional well-being
calculated by summing the Physical and Functional Well-being subscales
and the Prostate Cancer subscale.9 FACT-P subscales have been used in
clinical trials of QOL in patients with advanced PCa to characterize specific
domains.11-13
The FACT-Taxane (FACT-T) Scale includes 16 items associated with
adverse effects of taxane treatment, and it has excellent internal consis-
tency, reliability, validity, and responsiveness to change.14 Higher scores
indicate better QOL. A clinically meaningful difference in FACT-Taxane
was a change of$ 1 standard error of measurement.14 The Fatigue subscale
of the FACIT-F includes13 items that assess the physical experience of
fatigue.15 It exhibits strong convergent and discriminant validity, internal
consistency, test-retest reliability, and sensitivity to group differences in
performance status.15 Higher scores indicate better QOL. A minimal
important difference (MID) for FACIT-F was considered a change of $ 3
points.16 The Brief Pain Inventory (BPI) Short Form includes 11 questions
that assess pain intensity and interference with daily functioning.17,18 The
reliability and validity of the BPI are well established.17,18 Higher scores
indicate greater pain. MID was a change of $ 2 points for pain intensity
and $ 0.5 of the standard deviation for pain interference.19,20
In addition, we assessed QOL by PCa disease burden by comparing
FACT-P total scores and subscales between treatment arms by disease
burden.
Scoring Methods
FACT-P, FACT-T, and FACIT-F scores were calculated by summing
all subscale items after reversing negatively stated items. If items were
missing, subscale scores were prorated (we multiplied the sum of item
scores by the number of total subscale items, then divided by the number of
items answered) only if$ 50% of items in the subscale were answered. The
FACT-P total score was considered valid only if the FACT-P was $ 80%
complete. The BPI includes four items assessing pain intensity that were
averaged to determine the average pain score. The remaining seven pain
interference questions were averaged to obtain the average interference
score. Score calculation required $ 50% subscale completion. The re-
sponse rate was calculated by dividing the number of patients answering
any part of FACT-P by the number of patients due for an assessment.
Patients who died, refused follow-up, or were lost to follow-up were not
included in the denominator for the response rate.
Statistical Methods
We use descriptive statistics to characterize the patients at study entry
and the distribution of QOL scores. Fisher’s exact test was used to compare
response rates (compliance) between arms at each time point.21 Differ-
ences in the distribution of QOL scores between arms and changes in QOL
scores from baseline to follow-up were evaluated using the Wilcoxon rank
sum test and the Wilcoxon signed rank test, respectively.22 Mixed-effect
models with random intercepts for each individual were used to evaluate
the differences in FACT-P total scores and TOI between the two arms over
time.23 Several baseline factors, including age (# 59 years v 60 to 69 years
v$ 70 years), extent of disease (high volume v low volume), local therapy
(yes v no), ECOG performance scale (PS) (0 v 1 or 2), baseline physical
well-being (# 20 v 20 , physical well-being (PWB) # 25 v . 25), and
baseline pain score (0 or 1 v 2 or 3 v $ 4) were included in the model and
were considered to be fixed effects. The assessment time point was con-
sidered a categorical variable, and the interaction between treatment arm
and assessment time was included in the model. QOL data reflect all
jco.org © 2018 by American Society of Clinical Oncology 1089
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available data as of August 2015. All tests were two sided, and P values, .05
were considered significant.
RESULTS
Primary End Point: FACT-P
Between July 2006 andDecember 2012, 790men enrolled in E3805
and were randomly assigned to ADT+D (n = 397) or to ADT alone
(n = 393).3 Baseline characteristics were balanced between groups and
have been described previously (Table 1).3 The results of the survival
analysis of the study were released after a planned interim analysis in
October 2013 due to meeting prespecified criteria for significance.
FACT-P surveys were completed by 90%, 86%, 83%, 78%, and
77% of participants at baseline and at 3, 6, 9, and 12 months, re-
spectively (Table 2). Missing data rates were low, and there were similar
response rates at all time points other than at 3 and 9 months, when
there was a small but significantly better response rate for the ADT+D
arm (Table 2). Reasons formissing data are cataloged inAppendix Table
A1 (online only). A sensitivity analysis was performed using joint
modeling of QOL and survival data to adjust for nonignorable
missing data, and the conclusions were unchanged (Appendix
Table A2, online only).
For the primary end point, there was a statistically significant
decrease in the mean FACT-P score between baseline and 3 months
with ADT+D (22.7 points, P , .001), but no significant change in
mean FACT-P score between baseline and 3 months with ADT (21.1
points, P = .4; Fig 1A). There was no significant difference in mean
FACT-P score between baseline and 12 months with ADT+D (20.7
points, P = .38), but the mean FACT-P score significantly decreased
between baseline and 12 months with ADT (24.2 points, P , .001;
Appendix Table A3, online only). None of these changesmet the criteria
for a clinically meaningful change. A sensitivity analysis of the 25% of
men reporting the greatest decline in QOL between baseline and
3months was performed, and similar FACT-P score changes were seen.
A direct comparison of mean FACT-P total scores between
treatment arms at 3 months (during chemotherapy) showed no
significant difference (116.6 v 118.3, P = .07; Appendix Table A4,
online only). In a mixed-effects model adjusted as described in
Patients and Methods, the ADT+D group was associated with
a significantly poorer adjusted mean FACT-P score at 3 months
when compared with the ADT group (23.09, P = .02; Table 3).
Table 1. Patient Demographics and Disease Characteristics by Treatment Arm
Characteristic
Arm
Total (N = 790)ADT+D (n = 397) ADT (n = 393)
Age, y, median (range) 64 (36-88) 63 (39-91) 63 (36-91)
Ethnicity
White 344 (88.9) 330 (88.5) 674 (88.7)
Black 39 (10.1) 37 (9.9) 76 (10.0)
Asian 3 (0.8) 5 (1.3) 8 (1.1)
Native American 1 (0.3) 1(0.3) 2 (0.3)
Missing or unknown 10 20 30
ECOG PS
0 277 (69.8) 272 (69.4) 549 (69.6)
1 114 (28.7) 115 (29.3) 229 (29.0)
2 6 (1.5) 5 (1.3) 11 (1.4)
Missing or unknown 0 1 1
Extent of disease
High 263 (66.2) 249 (63.5) 512 (64.9)
Low 134 (33.8) 143 (36.5) 277(35.1)
Missing or unknown 0 1 1
Visceral disease (among high-volume disease patients)
No 206 (78.3) 183 (73.5) 389 (76.0)
Yes 57 (21.7) 66 (26.5) 123 (24.0)
Local therapy type
None 289 (72.8) 286 (73.0) 575 (72.9)
Prostatectomy 81 (20.4) 73 (18.6) 154 (19.5)
Definitive RT 27 (6.8) 33 (8.4) 60 (7.6)
Missing or unknown 0 1 1
PSA before ADT
No. 392 392 784
Nanogram/milliliter, median (range) 50.9 (0.2-8,540.1) 52.1 (0.1-8,056.0) 51.4(0.1-8,540.1)
Patients who started ADT before random assignment
No. 344 340 684
Time from start of ADT to random assignment, mo,
median (range)*
1.2 (0.03-3.9) 1.3 (0.03-3.9) 1.2 (0.03-3.9)
FACT-P total at baseline
No. 360 346 706
Mean (SD) 119.4 (20.1) 118.7 (22.1) 119.0 (21,1)
NOTE. Data are presented as No. (%) unless indicated otherwise.
Abbreviations: ADT, androgen deprivation therapy; ADT+D, docetaxel and androgen deprivation therapy; ECOG PS, Eastern Cooperative Oncology Group Performance
Scale; FACT-P, Functional Assessment of Cancer Therapy-Prostate; PSA, prostate-specific antigen; RT, radiation therapy.
*Among patients who started ADT before random assignment.
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Conversely, at 12 months, ADT+D was associated with a higher
mean adjusted FACT-P score when compared with that of ADT
(2.85, P = .04; Table 3). Differences between arms did not meet the
criteria for a clinically meaningful difference at any time point.
Secondary End Points
FACT-P subscales. We evaluated the TOI and FACT-P sub-
scales to determine the effect of treatment and disease on specific
domains of QOL (Appendix Table A4). At 3 months, mean TOI and
the physical and functional well-being subscales were significantly
lower with ADT+D thanwith ADTalone (TOI, 74.9 v 77.6, P= .003),
but they were similar at all other time points. In amixed-effects model
adjusted as described in Patients and Methods, ADT+D was asso-
ciated with significantly lower TOI scores than was ADTat 3 months
only (23.44, P , .001; Appendix Table A5, online only).
FACT-Taxane. We used the FACT-Taxane to assess the
treatment effect within and between arms over time. FACT-Taxane
Table 2. FACT-P Compliance by Treatment Arm
Treatment Arm
Response Rate at Assessment Time Points
Baseline 3 Months 6 Months 9 Months 12 Months
Total 90.3 (713 of 790) 86.4 (665 of 770) 83.4 (635 of 761) 78.3 (583 of 745) 77.0 (555 of 721)
ADT+D 92.2 (366 of 397) 89.9 (348 of 387) 83.8 (321 of 383) 81.3 (305 of 375) 77.5 (285 of 368)
ADT alone 88.3 (347 of 393) 82.8 (317 of 383) 83.1 (314 of 378) 75.1 (278 of 370) 76.5 (270 of 353)
P* .07 .005 .85 .04 .79
NOTE. Data are presented as % (No. patients with FACT-P submission out of the number of patients with quality of life [QOL] assessment due at each time point).
Patients who answered any part of the FACT-P questionnaire were considered to have submitted a FACT-P assessment for a given time point; patients who died, refused
follow-up, or were lost to follow-up before a given time point were not considered to have a QOL assessment due for that time point.
Abbreviations: ADT, androgen deprivation therapy; ADT+D, docetaxel and androgen deprivation therapy; FACT-P, Functional Assessment of Cancer Therapy-Prostate.
*Fisher’s exact test was used to compare the response rates between the two arms at each time point.
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Fig 1. Comparison of Functional Assessment of Cancer Therapy-Prostate (FACT-P) scores over time between the docetaxel and androgen deprivation therapy (ADT+D)
and androgen deprivation therapy (ADT) arms, including (A) FACT-P scores for the entire population; (B) FACT-P scores for high-volume patients; and (C) FACT-P scores for
low-volume patients. Clinically meaningful change on the FACT-P total score was considered a change of 6 to10 points.
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scores were significantly lower for ADT+D than for ADTat all time
points after baseline (Appendix Table A6, online only). FACT-
Taxane scores declined significantly from baseline in both treat-
ment arms at all time points (Fig 2A). No differences between
groups or changes over time met the criteria for MID.
FACIT-Fatigue. Mean scores for the FACIT-Fatigue were similar
between arms at baseline and at all subsequent time points, with
the exception of 3 months (36.1 v 40.4 for the ADT+D and ADT
arms at 3 months, respectively; P, .001; Appendix Table A6; Fig
2B). At 3 months, both the change in FACIT-Fatigue score from
baseline with ADT+D and the difference between arms met the
criteria for MID.
BPI. There was no significant difference between arms in BPI
pain intensity or interference scores at any time point (Figs 2C and
2D). Pain increased slightly over time in both groups but did not
meet the minimal clinically important difference at any time point
(Appendix Table A6).
High- Versus Low-Volume Disease
We assessed overall QOL between arms and over time by
comparing FACT-P scores by disease burden (Figs 1B and 1C).
There was no significant difference in mean FACT-P scores
between treatment arms within the high- or low-volume groups
(Appendix Table A7, online only). Among high-volume patients,
there was no significant change in mean FACT-P score between
baseline and any time point with ADT+D (Appendix Table A8,
online only). Among high-volume patients receiving ADT alone,
the mean FACT-P score at 12 months was significantly lower than
Table 3. Mixed-Effects Model* for FACT-P Total Score
Time Point
Difference between ADT+D and ADT Alone†
Estimate SE P
Baseline 21.00 1.28 .43
3 months 23.09 1.32 .02
6 months 0.90 1.34 .50
9 months 0.29 1.37 .84
12 months 2.85 1.39 .04
Abbreviations: ADT, androgen deprivation therapy; ADT+D, docetaxel and
androgen deprivation therapy; ECOG PS, Eastern Cooperative Oncology Group
Performance Scale; FACT-P, Functional Assessment of Cancer Therapy-Prostate;
PWB, physical well-being.
*With adjustment for age (# 59 years v 60 to 69 years v $ 70 years), extent of
disease (high v low), local therapy (yes v no), ECOG PS (0 v 1 or 2), baseline
physical well-being (# 20 v 20, PWB#25 v. 25), and baseline pain score (0 or
1 v 2 or 3 v $ 4); clinically meaningful change on the FACT-P total score was
considered a change of 6 to 10 points.
†ADT+DscoreminusADT alone score; higher scores represent better quality of life.
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Inventory (BPI) pain subscale; and (D) the BPI interference subscale.
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at baseline (23.9, P = .04; Appendix Table A8). Among ADT+D
low-volume patients, the mean FACT-P score decreased signif-
icantly between baseline and 3 months (25.3, P , .001), but
scores did not differ from baseline at 6, 9, or 12 months
(Appendix Table A8). Among ADT low-volume patients, the
mean FACT-P score was significantly lower than at baseline at all
time points (Appendix Table A8).
DISCUSSION
We assessed QOL over time in men treated with ADT+D or ADT
alone to assess the benefit-to-harm ratio of chemohormonal
therapy for mHSPC. Our data suggest that overall QOL declines for
men in the ADT+D arm at 3 months, but improves to nearly
baseline levels by 12 months. As we might expect, ADT+D was
associated with poorer physical and functional QOL at 3 months,
presumably because of treatment effects, but differences between
the groups resolved by 6 months. There was a gradual decline in
QOL over time in the ADT-alone arm, consistent with findings in
other metastatic PCa populations on effective hormonal therapy.24
Treatment burden as reflected by the FACT-Taxane demonstrated
significantly poorer scores among men treated with ADT+D than
with ADT alone at all time points after baseline. Fatigue was
significantly greater in the ADT+D arm when compared with
ADT only at 3 months, and pain intensity and interference were
similar between arms at all time points. Although the identified
differences were significantly different statistically, changes in
QOL did not meet the criteria for clinically meaningful change by
any measure.
When using the findings from this study in clinical de-
cisions, individual patient characteristics, specific comorbidities,
performance status, and other psychosocial factors that may
contribute to a patient’s tolerance of treatment and treatment
experience should be considered. This patient population rep-
resents a slightly younger age than the average age of men with
PCa (median age of 63 years in the E3805 Chemohormonal
Androgen Ablation Randomized Trial in Prostate Cancer
[CHAARTED] v median age of 66 years in men with PCa), and
a majority have high-volume metastatic disease (64.9% overall)
and an ECOG performance status of 0 (nearly 70%) or 1 (ap-
proximately 29%).2 The findings may be less applicable to older,
frailer men and should be considered in concert with the
updated analysis that fails to find a survival advantage from
chemohormonal therapy in men with low-volume disease.5
Clinicians should also consider QOL data from treatment
with ADT, abiraterone acetate, and prednisone until progres-
sion in the mHSPC setting.26,27 Abiraterone acetate and che-
mohormonal therapy may confer similar survival benefits in
this patient population, and considerations of differences in the
adverse effect profile of long-term abiraterone acetate and
prednisone are likely to be distinct from those associated with
six cycles of docetaxel and ongoing ADT.28
Although patient-reported outcomes are commonly in-
corporated into PCa clinical trials for localized disease, they have
been less consistently included in studies of advanced PCa.29-31 A
challenge for the field has been a lack of consistency across
studies in the QOL instruments included in trials of advanced
PCa, making comparisons of different treatment approaches less
than straightforward. Treatment trials in men with metastatic
PCa have not consistently demonstrated a significant change in
global measures of QOL.8,32 To address this, we included an
analysis of FACT-P subscales and additional QOL instruments
and compared QOL between and within arms, to provide a more
nuanced description of QOL than could be provided by relying
on a single instrument alone.
To our knowledge, this prospective, randomized study is the
first QOL comparison between chemohormonal therapy and ADT
alone, and the first longitudinal analysis of these treatments. As
clinicians determine whether to guide decisions by overall survival
data in CHAARTED, LATITUDE, and STAMPEDE, by CHAARTED
subgroup analysis data for high- versus low-volume mHSPC, or by
QOL data from these studies, this QOL analysis will enable them to
consider the QOL effects of these treatments in the shared
decision-making process.3-5,26,27,33 This study is limited in that
the analysis cannot definitively attribute detriments in QOL to
treatment or disease progression with the included instruments,
although FACT-T changes are likely more specific to treatment
than to disease progression. However, to the best of our knowledge,
it is the most comprehensive study of the QOL to date in this
patient population. The longitudinal data demonstrating an
improvement in overall QOL at 12 months in the chemo-
hormonal arm suggests that the physical and functional deficits
present at the 3-month time point are reversible short-term
deficits. Because participants were not blinded to treatment,
it is also possible that the knowledge of having received an ad-
ditional treatment (chemotherapy) might have affected their
perspective and QOL reports, although this was likely reduced
by the comprehensive assessment of diverse aspects of QOL
(physical, functional, prostate cancer [PCa] specific, and so
forth). In addition, we report QOL differences that were sta-
tistically significant as reported by patients, but we cannot define
within this study how clinically meaningful they were to patients.
Separate work has defined clinically meaningful change in the
QOL measures used in various clinical settings.10,14,16,19,20 Clinically
meaningful differences can be calculated by multiple methods,
including anchoring to patient-reported global rating scales or
objective physician-designated clinical measures (eg, performance
status), or on the basis of standard deviation within a cohort.34,35
Although the differences in QOL in this study did not meet pre-
viously defined MID levels, these changes and differences were
rigorously collected from patients during treatment and are a valid
patient-reported contribution to consider when choosing treatment
of mHSPC. Finally, we acknowledge that this study does not report
on late effects from treatment that may be important in clinical
decision making.
This analysis compares the QOL of men receiving ADT+D
and ADT alone, assesses QOL over time with multiple in-
struments, and evaluates QOL by disease burden. Men treated
with ADT+D had poorer QOL outcomes than did men treated
with ADT alone at 3 months while undergoing chemotherapy.
However, by 12 months, ADT+D patients reported statistically
superior overall QOL outcomes by FACT-P. These findings
must be considered in the context of the population assessed
and in the context of a simultaneously reported subgroup
analysis that failed to find an improvement in overall survival in
jco.org © 2018 by American Society of Clinical Oncology 1093
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men with low-volume mHSPC treated with ADT+D. Clinicians
treating men with mHSPC who are fit enough to receive
chemotherapy should consider that ADT+D is associated with
both stable to improved QOL at 12 months and greater lon-
gevity than ADT alone.
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Appendix
Descriptive statistics were used to characterize reasons for Functional Assessment of Cancer Therapy-Prostate (FACT-P)
noncompliance and the distribution of quality of life (QOL) scores. Differences in the distribution of QOL scores between arms and
changes in QOL scores from baseline to follow-up were evaluated using the Wilcoxon rank sum test and the Wilcoxon signed rank
test, respectively.22 Distribution of FACT-P total scores and changes from baseline were also presented by volume of disease and
among the 25% of patients with the greatest alterations at 3 months. Mixed-effect models with random intercepts for each
individual were used to evaluate the differences in Trial Outcome Index score between the two arms over time.23 Several baseline
factors, including age (# 59 years v 60 to 69 years v$ 70 years), extent of disease (high volume v low volume), local therapy (yes v
no), Eastern Cooperative Oncology Group PS (0 v 1 or 2), baseline physical well-being (# 20 v 20, PWB# 25 v. 25) and baseline
pain score (0 or 1 v 2 or 3 v $ 4) were included in the model and were considered to be fixed effects. Assessment time point was
considered a categorical variable, and the interaction between treatment arm and assessment time was included in the model. A
joint model (Schluchter MD: Methods for the analysis of informatively censored longitudinal data. Stat Med 11(14-15):1861-1870,
1992) of longitudinal FACT-P measurements and survival data was performed to explore the trend of QOL changes over time. The
mean slope of FACT-P scores over time was estimated for each arm, and bootstrap standard errors were computed. QOL data reflect
all available data as of August 2015. All tests were two sided, and P values , .05 were considered significant.
Metastatic prostate cancer
Randomly assigned to ADT+D
(n = 397)
(Androgen deprivation + docetaxel)
Ineligible
Eligibility status not finalized
(n = 4)
(n = 5)
Did not start treatment (excluded from
toxicity analysis):
Patient withdrawal/refusal before
beginning protocol therapy
Medical decision
No treatment information submitted
(n = 5)
(n = 1)
(n = 1)
Follow-up status as of December 23, 2014:
No follow-up
Follow-up submitted
Documented lost to follow-up
Withdrew consent/patient refusal
Follow-up status as of ASCO presentation:
No follow-up
(n = 0)
(n = 397)
(n = 3)
(n = 11)
(n = 0)
In primary analysis
In toxicity analysis
(n = 397)
(n = 390)
Randomly assigned to ADT alone
(n = 393)
(Androgen deprivation alone)
Did not start treatment: N/A
Ineligible
Eligibility status not finalized
(n = 6)
(n = 2)
Follow-up status as of December 23, 2014:
No follow-up (n = 1, excluded from toxicity
analysis)
Follow-up submitted
Documented lost to follow-up
Withdrew consent/patient refusal
Follow-up status as of ASCO presentation:
No follow-up
(n = 392)
(n = 0)
(n = 14)
(n = 2)
In primary analysis
In toxicity analysis
(n = 393)
(n = 392)
Fig A1. CONSORT diagram. ADT+D, docetaxel and androgen deprivation therapy; ADT, androgen deprivation therapy.
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Table A1. Reasons for FACT-P Noncompliance by Arm Over Time*
Reason
Baseline 3 Months 6 Months 9 Months 12 Months
ADT+D ADT ADT+D ADT ADT+D ADT ADT+D ADT ADT+D ADT
Patient refusal 5 6 6 7 5 10 7 14 8 10
Unable to accommodate disability or language needs 0 0 0 0 0 0 0 0 0 0
Patient did not show up in clinic or office 0 1 1 7 1 5 4 3 4 5
Staff unavailable 0 1 0 2 1 3 1 4 2 2
Patient not given form by staff 2 12 12 21 24 16 25 30 27 22
Patient too ill 0 0 1 0 1 2 1 0 0 1
Patient expired 0 0 0 0 0 0 0 2† 0 1‡
Assessment not required per protocol 0 0 0 0 0 1 0 1 1 1
Staff thought patient too ill 0 0 0 2 2 0 1 0 1 0
Patient did not show up in clinic or patient too ill 0 0 0 0 0 1 0 0 0 0
Staff unavailable or patient not given form by staff 0 0 0 0 1 1 2 1 0 0
Patient refusal or patient did not show up in clinic 0 0 0 0 0 0 0 0 1 1
Patient too ill or staff thought patient too ill 0 0 0 0 0 0 0 0 1 0
Staff thought patient too ill or patient not given form by staff 0 0 0 0 0 0 0 0 0 1
Patient did not show up in clinic or patient not given form by
staff or patient too ill or staff thought patient too ill
0 0 0 0 0 1 0 0 0 0
Other 0 2 2 6 7 3 4 8 6 13
Unknown or missing 24 24 17 21 20 21 25 29 32 26
Total 31 46 39 66 62 64 70 92 83 83
Abbreviations: ADT, androgen deprivation therapy; ADT+D, docetaxel and androgen deprivation therapy; FACT-P, Functional Assessment of Cancer Therapy-Prostate.
*Research staff submitted one reason for why the form was not completed in all but a few instances in which multiple reasons were submitted (these are listed in the
latter half of the table).
†Two patients died shortly after 9 months from random assignment. They were alive at the FACT-P assessment time point (month 9), so forms are considered due for the
9-month evaluation.
‡One patient died shortly after 12months from random assignment. He was alive at the FACT-P assessment time point (month 12), so forms are considered due for the
12-month evaluation.
Table A2. Estimation of Mean Slope of FACT-P Score in a Joint Model of QOL
Assessments and Survival Data
Treatment Arm
Baseline to 3
Months
3 Months to 12
Months
Slope* SE† Slope* SE†
ADT+D 20.7 1.5 0.9 1.5
ADT alone 0.6 0.5 20.6 0.2
Abbreviations: ADT, androgen deprivation therapy; ADT+D, docetaxel and
androgen deprivation therapy; FACT-P, Functional Assessment of Cancer
Therapy-Prostate; QOL, quality of life.
*FACT-P score change/month.
†Bootstrap standard error.
Table A3. Distributions of Changes from Baseline to Follow-Up for FACT-P Total Scores*
Change
ADT+D ADT Alone
No. Mean SE Median Range† P† No. Mean SE Median Range P
From baseline to 3 months 334 22.7 0.9 23.0 253.2-59.5 .0009 299 21.1 1.0 0.0 263.0-61.7 .4000
From baseline to 6 months 307 20.7 0.8 21.0 245.0-63.0 .2100 294 22.5 0.9 21.0 269.4-64.0 .0070
From baseline to 9 months 293 21.4 1.0 20.4 255.3-58.8 .2500 263 22.6 1.0 21.3 282.2-49.3 .0100
From baseline to 12 months 269 20.7 1.1 21.6 282.3-72.0 .3800 253 24.2 1.1 23.8 265.4-51.0 .0004
Abbreviations: ADT, androgen deprivation therapy; ADT+D, docetaxel and androgen deprivation therapy; FACT-P, Functional Assessment of Cancer Therapy-Prostate.
*Total score = physical + social/family + emotional + functional + prostate cancer additional concerns; clinically meaningful change on the FACT-P total score was
considered a change of 6 to 10 points.
†Wilcoxon signed rank test comparing follow-up scores and baseline scores in each arm.
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Table A4. Distribution of FACT-P Total Scores and Subscale Scores Over Time by Arm
ADT+D ADT alone
P* (rank sum)No. Mean SE Median Range No. Mean SE Median Range
Total score†
Baseline 360 119.4 1.1 123.1 47-156 346 118.7 1.2 123.5 43.7-153.9 .9100
3 months 344 116.6 1.1 118.0 39.6-155 313 118.3 1.2 123.8 45-155 .0700
6 months 318 118.4 1.1 121.0 49-156 310 116.7 1.3 120.5 44.0-156 .5200
9 months 304 118.4 1.2 122.0 40-154.9 273 117.5 1.3 123.0 29.8-154.8 .7000
12 months 279 119.2 1.3 122.8 52-156 265 116.4 1.3 120.0 42.8-156 .0900
TOI‡
Baseline 363 78.7 0.8 82.0 25-104 347 77.8 0.9 82.4 15-104 .9200
3 months 345 74.9 0.8 76.0 23.6-103 314 77.6 1.0 82.5 16.4-104 .0030
6 months 319 76.9 0.9 79.0 19-104 312 76.3 1.0 80.0 20.8-104 .9600
9 months 305 76.8 0.9 80.0 10-104 275 76.8 1.0 81.0 23-102.8 .8100
12 months 279 77.4 1.0 80.0 18-104 266 75.7 1.0 78.0 20.4-104 .2100
Physical
Baseline 366 24.1 0.2 26.0 7-28 347 23.7 0.3 25.0 0-28 .3900
3 months 347 21.4 0.3 23.0 5-28 315 23.0 0.3 25.0 0-28 ,.0001
6 months 320 22.8 0.2 23.7 4-28 313 23.0 0.3 25.0 4-28 .1200
9 months 305 23.0 0.3 24.0 2-28 276 22.9 0.3 25.0 5-28 .7100
12 months 283 22.7 0.3 24.0 2-28 269 22.4 0.3 24.0 1-28 .4400
Social/family
Baseline 365 22.9 0.2 24.0 0-28 347 22.7 0.3 24.0 0-28 .4000
3 months 346 22.6 0.2 23.3 0-28 314 22.4 0.2 23.3 7-28 .3800
6 months 320 22.6 0.3 24.0 0-28 313 21.9 0.3 23.0 0-28 .0600
9 months 304 22.7 0.3 24.0 0-28 275 22.2 0.3 23.3 0-28 .0900
12 months 283 22.7 0.3 24.0 0-28 268 22.1 0.3 23.0 3-28 .0700
Emotional
Baseline 363 17.8 0.2 18.0 2-24 346 18.1 0.2 19.0 3-24 .1000
3 months 347 19.0 0.2 20.0 5-24 317 18.4 0.2 19.0 0-24 .0800
6 months 318 18.9 0.2 20.0 6-24 313 18.3 0.2 19.0 6-24 .0700
9 months 305 18.9 0.2 20.0 0-24 275 18.5 0.2 19.0 1-24 .1300
12 months 281 19.1 0.3 20.0 2-24 268 18.5 0.3 19.6 5-24 .0600
Functional
Baseline 363 20.4 0.3 21.0 0-28 347 20.1 0.3 21.0 0-28 .5800
3 months 347 19.1 0.3 19.0 3-28 317 20.4 0.3 21.0 2-28 .0030
6 months 319 19.9 0.3 20.0 2-28 313 19.7 0.4 21.0 0-28 .9000
9 months 305 20.1 0.3 21.0 3-28 276 20.1 0.4 21.0 3-28 .8900
12 months 281 20.3 0.4 21.0 4-28 266 20.2 0.3 21.0 2-28 .6400
PCa§
Baseline 366 34.2 0.4 36.0 7-48 347 34.0 0.4 36.0 10-48 .9100
3 months 346 34.4 0.4 35.0 7-48 316 34.0 0.4 36.0 8.4-48 .7500
6 months 320 34.2 0.4 35.0 3-48 313 33.6 0.4 34.9 9.8-48 .3200
9 months 305 33.7 0.4 35.0 3-48 277 33.8 0.4 35.0 8-48 .8100
12 months 282 34.3 0.4 35.0 11-48 268 33.0 0.5 33.0 12-48 .0400
Abbreviations: ADT, androgen deprivation therapy; ADT+D, docetaxel and androgen deprivation therapy; FACT-P, Functional Assessment of Cancer Therapy-Prostate;
PCa, prostate cancer; TOI, Trial Outcome Index.
*Wilcoxon rank sum test between the two arms for each subscale at each time point.
†Total score = physical + social/family + emotional + functional + PCa additional concerns; clinically meaningful change on the FACT-P total score was considered
a change of 6 to 10 points.
‡TOI = physical + functional + prostate cancer additional concerns.
§PCa-specific concerns subscale.
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Table A5. Mixed-Effects Model* for TOI Score
Time Point
Difference Between ADT+D and ADT Alone†
Estimate SE P
Baseline 20.55 0.96 .5700
3 months 23.44 1.00 .0005
6 months 0.22 1.01 .8300
9 months 20.40 1.04 .7000
12 months 1.75 1.06 .1000
Abbreviations: ADT, androgen deprivation therapy; ADT+D, docetaxel and
androgen deprivation therapy; TOI, Trial Outcome Index.
*With adjustment for age (# 59 years v 60 to 69 years v $ 70 years), extent of
disease (high v low), local therapy (yes v no), Eastern Cooperative Oncology
Group Performance Scale (0 v 1 or 2), baseline physical well-being (# 20 v 20 ,
PWB # 25 v . 25), and baseline pain score (0 or 1 v 2 or 3 v $ 4).
†ADT+D score minus ADT alone score.
Table A6. Distribution of Additional QOL Scores Over Time by Treatment Arm, Including FACT-Taxane, FACIT-Fatigue, and Brief Pain Index Pain and
Interference Scores
Arm A (ADT+D) Arm B (ADT alone)
P*No. Mean SD No. Mean SD
FACT-Taxane†
Baseline 361 58.2 6.1 346 57.4 7.4 .6800
3 months 345 54.1 8.7 312 56.4 8.1 ,.0001
6 months 318 52.7 9.7 305 56.1 7.8 ,.0001
9 months 306 53.7 8.5 273 55.4 8.6 .0030
12 months 282 53.6 8.6 266 54.9 8.4 .0300
FACIT-Fatigue‡
Baseline 361 41.9 9.7 346 40.9 10.7 .4400
3 months 339 36.1 11.3 312 40.4 10.8 ,.0001
6 months 318 39.4 10.0 308 40.2 10.4 .1400
9 months 301 39.6 10.3 277 40.1 10.7 .3400
12 months 280 39.4 10.7 265 38.4 11.2 .3200
Pain score§
Baseline 337 1.6 1.8 326 1.7 1.9 .5000
3 months 323 1.7 1.9 298 1.9 2.1 .2900
6 months 298 2.0 2.1 298 1.8 2.1 .1200
9 months 290 2.2 2.2 265 1.9 2.1 .1800
12 months 272 2.0 2.0 261 2.0 1.9 .6700
Interferencek
Baseline 339 1.5 2.1 317 1.6 2.3 .8500
3 months 316 1.6 2.2 290 1.8 2.3 .6000
6 months 292 2.0 2.4 289 1.8 2.4 .1500
9 months 288 2.0 2.3 258 1.8 2.4 .0800
12 months 263 1.9 2.3 257 1.9 2.2 .8400
Abbreviations: ADT, androgen deprivation therapy; ADT+D, docetaxel and androgen deprivation therapy; FACIT-Fatigue, Functional Assessment of Chronic Illness
Therapy-Fatigue; FACT-Taxane, Functional Assessment of Cancer Therapy-Taxane; QOL, quality of life.
*Wilcoxon rank sum test between the two arms at each time point.
†Clinically meaningful important difference in FACT-Taxane was a change of $ 1 standard error of measurement.
‡Minimal important difference for FACIT-Fatigue was considered a change of $ 3 points.
§Average score of the four pain questions (worst, least, average, and now), where 0 = no pain and 10 = pain as bad as you can imagine;minimal important differencewas
a change of $ 2 points for pain intensity.
kAverage score of the seven interference questions, where 0 = does not interfere and 10 = completely interferes; minimal important difference was $ 0.5 of the
standard deviation for pain interference.
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Table A7. Distribution of FACT-P Total Score* Over Time by Arm and Disease Volume
Time Point
ADT+D ADT alone
P†
(rank sum)N Mean SE Median Range N Mean SE Median Range
High volume
Baseline‡ 234 118.2 1.4 121.5 47-156 213 116.1 1.6 120.8 43.7-153.9 .48
3 months 223 116.3 1.3 117 39.6-155 191 117.0 1.6 122.0 57.4-154 .35
6 months 205 117.8 1.4 120 49-156 187 114.7 1.6 117.0 44.0-156 .21
9 months 191 117.8 1.5 121 40-154.9 159 115.3 1.7 120.0 29.8-154.8 .30
12 months 170 118.0 1.6 120.9 52-156 149 113.7 1.8 117.0 42.8-156 .10
Low volume
Baseline‡ 126 121.6 1.6 126 59-152.8 133 122.9 1.7 128.0 64-152 .30
3 months 121 117.0 2.0 121 56-151 122 120.3 2.0 128.5 45-155 .12
6 months 113 119.5 1.8 122 59-151 123 119.7 1.9 126.0 55.5-152 .70
9 months 113 119.4 2.0 123 52-152 114 120.5 1.9 125.9 65.3-149.7 .63
12 months 109 121.0 2.1 125 54.5-151 116 120.0 1.8 121.0 57.4-152 .36
Abbreviations: ADT, androgen deprivation therapy; ADT+D, docetaxel and androgen deprivation therapy; FACT-P, Functional Assessment of Cancer Therapy-Prostate.
*Total score = physical + social/family + emotional + functional + prostate cancer additional concerns; clinically meaningful change on the FACT-P total score was
considered a change of 6 to 10 points.
†Wilcoxon rank sum test between the two arms for each subscale at each time point.
‡Wilcoxon rank sum test was used to compare baseline FACT-P total score between high-volume and low-volume patients. Patients with low-volume disease had
higher FACT-P scores than did high-volume patients at baseline (P = .003).
Table A8. Distributions of Changes From Baseline to Follow-Up for FACT-P Total Scores by Arm and Disease Volume*
Change
ADT+D ADT alone
No. Mean SE Median Range P† No. Mean SE Median Range P†
High volume
From baseline to 3 months 215 21.30 1.1 21.20 253.2-59.5 .1300 183 0.41 1.4 0.33 263.0-61.7 .560
From baseline to 6 months 197 0.03 1.1 20.70 245.0-47.0 .8100 177 21.50 1.3 21.0 269.4-64.0 .310
From baseline to 9 months 183 21.00 1.3 0.00 255.3-45.0 .5100 152 22.10 1.4 21.4 282.2-49.3 .130
From baseline to 12 months 162 20.30 1.4 22.75 246.0-72.0 .3700 143 23.9 1.6 23.2 265.4-51.0 .040
Low volume
From baseline to 3 months 119 25.30 1.4 24.00 251.0-47.8 .0003 116 23.5 1.3 21.0 256.0-33.8 .020
From baseline to 6 months 110 22.00 1.3 22.00 238.0-63.0 .0700 117 24.1 1.2 22.0 243.0-30.0 .002
From baseline to 9 months 110 22.00 1.5 21.00 250.0-58.8 .3400 111 23.2 1.2 21.3 244.0-27.5 .040
From baseline to 12 months 107 21.20 1.7 21.00 282.3-53.0 .8400 110 24.6 1.4 24.0 249.7-37.0 .001
Abbreviations: ADT, androgen deprivation therapy; ADT+D, docetaxel and androgen deprivation therapy; FACT-P, Functional Assessment of Cancer Therapy-Prostate.
*Total score = physical + social/family + emotional + functional + prostate cancer additional concerns; clinically meaningful change on the FACT-P total score was
considered a change of 6 to 10 points.
†Wilcoxon signed rank test comparing follow-up scores and baseline scores in each arm.
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